JP6495434B2 - サーファクタントタンパク質ａ受容体を標的とする組成物及び方法 - Google Patents

サーファクタントタンパク質ａ受容体を標的とする組成物及び方法 Download PDF

Info

Publication number
JP6495434B2
JP6495434B2 JP2017502246A JP2017502246A JP6495434B2 JP 6495434 B2 JP6495434 B2 JP 6495434B2 JP 2017502246 A JP2017502246 A JP 2017502246A JP 2017502246 A JP2017502246 A JP 2017502246A JP 6495434 B2 JP6495434 B2 JP 6495434B2
Authority
JP
Japan
Prior art keywords
sequence
cells
seq
monoclonal antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017502246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527268A5 (https=
JP2017527268A (ja
Inventor
クロネオス，ジシス
クリステンセン，ニール
Original Assignee
ザ ペン ステイト リサーチ ファンデーション
ザ ペン ステイト リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ペン ステイト リサーチ ファンデーション, ザ ペン ステイト リサーチ ファンデーション filed Critical ザ ペン ステイト リサーチ ファンデーション
Publication of JP2017527268A publication Critical patent/JP2017527268A/ja
Publication of JP2017527268A5 publication Critical patent/JP2017527268A5/ja
Application granted granted Critical
Publication of JP6495434B2 publication Critical patent/JP6495434B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017502246A 2014-07-14 2015-07-14 サーファクタントタンパク質ａ受容体を標的とする組成物及び方法 Active JP6495434B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462024314P 2014-07-14 2014-07-14
US62/024,314 2014-07-14
US201562121830P 2015-02-27 2015-02-27
US62/121,830 2015-02-27
PCT/US2015/040304 WO2016010978A1 (en) 2014-07-14 2015-07-14 Compositions and methods for targeting of the surfactant protein a receptor

Publications (3)

Publication Number Publication Date
JP2017527268A JP2017527268A (ja) 2017-09-21
JP2017527268A5 JP2017527268A5 (https=) 2018-04-19
JP6495434B2 true JP6495434B2 (ja) 2019-04-03

Family

ID=55078969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502246A Active JP6495434B2 (ja) 2014-07-14 2015-07-14 サーファクタントタンパク質ａ受容体を標的とする組成物及び方法

Country Status (8)

Country Link
US (1) US10077309B2 (https=)
EP (2) EP3733700A1 (https=)
JP (1) JP6495434B2 (https=)
CN (1) CN106604931B (https=)
AU (2) AU2015289831B2 (https=)
CA (2) CA3225495A1 (https=)
ES (1) ES2869909T3 (https=)
WO (1) WO2016010978A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
CN116217718B (zh) * 2022-11-21 2023-08-25 浙江洪晟生物科技股份有限公司 一种猪丹毒抗体检测试剂盒及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE921342A1 (en) * 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
EP1649038B1 (en) 2003-06-26 2014-07-02 Litron Laboratories Ltd. Method for the enumeration of micronucleated erythrocyte populations while distinguishing platelets and/or platelet-associated aggregates
US8691730B2 (en) * 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8748113B2 (en) 2007-11-15 2014-06-10 The Johns Hopkins University Methods for detecting and monitoring circulating cancer stem cells
WO2010010467A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
CN104936977B (zh) 2012-10-24 2019-10-08 开普敦大学 微管修饰化合物

Also Published As

Publication number Publication date
CA3225495A1 (en) 2016-01-21
AU2020294340B2 (en) 2024-05-02
CN106604931A (zh) 2017-04-26
ES2869909T3 (es) 2021-10-26
CA2954518A1 (en) 2016-01-21
US10077309B2 (en) 2018-09-18
EP3733700A1 (en) 2020-11-04
AU2015289831B2 (en) 2021-01-28
CN106604931B (zh) 2020-04-21
US20170158768A1 (en) 2017-06-08
AU2020294340A1 (en) 2021-02-25
WO2016010978A1 (en) 2016-01-21
EP3172230A1 (en) 2017-05-31
EP3172230A4 (en) 2018-04-18
JP2017527268A (ja) 2017-09-21
CA2954518C (en) 2024-02-20
AU2015289831A1 (en) 2017-02-09
EP3172230B1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
US20220162331A1 (en) Anti-cd73 monoclonal antibody and application thereof
CN111356701B (zh) 抗α-突触核蛋白抗体及其用途
JP7065786B2 (ja) 肝病態を治療又は予防する方法
TR201808018T4 (tr) Anti-B7-H3 antikoru.
JP2023538369A (ja) 抗ｃｄ７３抗体とその使用
KR20160062167A (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
EP3220952B1 (en) Method of treating or preventing stroke
AU2020294340B2 (en) Compositions and methods for targeting of the surfactant protein a receptor
CN113015751A (zh) 一种融合蛋白及其用途
CN109384845B (zh) 一种cd40单克隆抗体、其制备方法及其应用
US12358977B2 (en) Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the IL-20R
JP6263117B2 (ja) 抗ｃｘａｄｒ抗体
JP2024509973A (ja) Ｔｄｐ－４３に対する抗体およびその使用方法
US11655298B2 (en) Composition for treating fulminant acute pneumonia including CD69 antagonist
JP6944701B2 (ja) ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物
HK40022840B (zh) 抗α-突触核蛋白抗体及其用途
HK1242603B (en) Method of treating or preventing stroke

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190306

R150 Certificate of patent or registration of utility model

Ref document number: 6495434

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250